Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficlatuzumab with HiDAC in Relapsed/Refractory AML
NCT02109627Phase 1Terminated
- Start
- May 2015
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ficlatuzumab in acute myeloid leukemia (AML). Primary endpoints: Dose-Limiting Toxicity up to 2 years and Maximum Tolerated Dose up to 2 years. Started May 2015; status: terminated.
02
Drugs
ficlatuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02109627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109627.